Unknown

Dataset Information

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure.


ABSTRACT:

Aims

To determine the incidence of hyperkalaemia in patients with heart failure with reduced ejection fraction (HFrEF) during up-titration of guideline-directed medical therapy (GDMT) in real-world settings.

Methods

A retrospective review of medical records of all patients hospitalized for newly onset HFrEF at Sahlgrenska University Hospital, Sweden, between 1 January 2016 and 31 December 2019. Based on mineralocorticoid receptor antagonist (MRA) treatment within the first 6 months, patients were divided into four groups: (i) never received MRA, (ii) needed MRA dose reduction, (iii) needed discontinuation of MRA, and (iv) stable MRA treatment. Potassium levels were assessed at baseline and has the highest potassium level during the 6 months of up-titration.

Results

Of

SUBMITTER: Henrysson J 

PROVIDER: S-EPMC9871699 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature